Loading...
Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other a...
Na minha lista:
| Udgivet i: | Eur Endocrinol |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Touch Medical Media
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5813455/ https://ncbi.nlm.nih.gov/pubmed/29632584 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.17925/EE.2016.12.01.31 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|